EDUCAÇÃO, CIÊNCIA E TECNOLOGIA: DA CONSTITUINTE AO PLANO COLLOR

Analyses resulting from the research project on The University, Scienceand Technology in the Constituent Assembly and from the study of present policiesin education, science and technology take as their central theme the issueof “Less State”. This article proposes to show, through the discussion of corporatismand “*neo-liberalism in Brazil, a line of continuity in the last few years withrespect to relations between the State and civil society, and the resulting possibilities(and limits) of public policies for these sectors in BrazilLa présentation de quelques analyses qui résultent du projet de recherchesur L’Université, Science et Techonologie dans TAssemblée Constituante et derecherches sur les politiques actuelles en éducation, science et technologie débouchentsur la question de ‘TEtat Minimum”. L’article cherche à montrer, par ladiscussion du corporatisme et du “néo-libéralisme” brésiliens, une ligne de continuitéen ce qui concerne les rapports Etat/société civile et les conséquencesen termes de possibilités et limites des politiques publiques pour ces secteursau Brésil.A exposição de algumas análises resultantes da pesquisa Universidade,Ciência e Tecnologia na Constituinte e das políticas atuais em educação, ciênciae tecnologia tem como eixo central a questão do “Estado Mínimo”. Procurasemostrar aqui, discutindo a questão do corporativismo e as interpretaçõesbrasileiras do “neo-liberalismo”, uma linha de continuidade nas relações Estado/sociedade civil e nas conseqüentes possibilidades (e limites) da implementaçãode políticas públicas nessas área

Programa de Excelência em Gestão: o caso da Frísia Cooperativa Agroindustrial

This case study addresses the application of the Management Excellence Program at Frísia Cooperativa Agroindustrial, using the Cooperative Management Development Program tool (PDGC), which is based on the Management Excellence Model (MEG) of the National Quality Foundation (FNQ). We evaluate the applicability of the tool which makes a diagnosis of the governance and management structure of the cooperative and aims at continuous improvement in each PDCL (Plan, Do, Check, and Learn) cycle. In order to get more information, we carried out a semi-structured interview with the governance agents of Frísia. The data (made available by SESCOOP-PR, with the consent of the cooperative) refers to the PDGC cycles of 2017 and 2018. Results show that the SESCOOP Cooperative Governance Index (ISGC) increased from 63.3% in 2017 to 87.0% in 2018, as well as the SESCOOP Management Index (ISG), which increased from 50.3% in 2017 to 69.4% in 2018.Este estudo de caso aborda a aplicação do Programa de Excelência em Gestão na Frísia Cooperativa Agroindustrial, utilizando a ferramenta do Programa de Desenvolvimento da Gestão das Cooperativas (PDGC), que faz um diagnóstico da governança e da gestão da cooperativa, visando à melhoria contínua a cada ciclo de planejamento, execução, controle e aprendizado. Foram disponibilizados dados pelo SESCOOP-PR, com anuência da cooperativa, referente aos ciclos do PDGC dos anos de 2017 e 2018. Verificou-se que o Índice SESCOOP de Governança Cooperativista (ISGC) passou de 63,3% em 2017 para 87,0% em 2018. E o Índice SESCOOP de Gestão (ISG) passou de 50,3% em 2017 para 69,4% em 2018. Para complementar as informações, foi realizada uma entrevista semiestruturada com os agentes de governança da Frísia. A análise dos resultados indica que uma estrutura de governança capaz de integrar as diferentes partes interessadas tem efeitos práticos na efetividade da gestão da cooperativa.

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

Altres ajuts: Beca PERIS 2018-2020 de la Generalitat de Catalunya (BDNS357800

Patient listening on social media for patient-focused drug development: a synthesis of considerations from patients, industry and regulators

Patients, life science industry and regulatory authorities are united in their goal to reduce the disease burden of patients by closing remaining unmet needs. Patients have, however, not always been systematically and consistently involved in the drug development process. Recognizing this gap, regulatory bodies worldwide have initiated patient-focused drug development (PFDD) initiatives to foster a more systematic involvement of patients in the drug development process and to ensure that outcomes measured in clinical trials are truly relevant to patients and represent significant improvements to their quality of life. As a source of real-world evidence (RWE), social media has been consistently shown to capture the first-hand, spontaneous and unfiltered disease and treatment experience of patients and is acknowledged as a valid method for generating patient experience data by the Food and Drug Administration (FDA). While social media listening (SML) methods are increasingly applied to many diseases and use cases, a significant piece of uncertainty remains on how evidence derived from social media can be used in the drug development process and how it can impact regulatory decision making, including legal and ethical aspects. In this policy paper, we review the perspectives of three key stakeholder groups on the role of SML in drug development, namely patients, life science companies and regulators. We also carry out a systematic review of current practices and use cases for SML and, in particular, highlight benefits and drawbacks for the use of SML as a way to identify unmet needs of patients. While we find that the stakeholders are strongly aligned regarding the potential of social media for PFDD, we identify key areas in which regulatory guidance is needed to reduce uncertainty regarding the impact of SML as a source of patient experience data that has impact on regulatory decision making

Diet and BMI Correlate with Metabolite Patterns Associated with Aggressive Prostate Cancer

Three metabolite patterns have previously shown prospective inverse associations with the risk of aggressive prostate cancer within the European Prospective Investigation into Cancer and Nutrition (EPIC). Here, we investigated dietary and lifestyle correlates of these three prostate cancer-related metabolite patterns, which included: 64 phosphatidylcholines and three hydroxysphingomyelins (Pattern 1), acylcarnitines C18:1 and C18:2, glutamate, ornithine, and taurine (Pattern 2), and 8 lysophosphatidylcholines (Pattern 3). In a two-stage cross-sectional discovery (n = 2524) and validation (n = 518) design containing 3042 men free of cancer in EPIC, we estimated the associations of 24 dietary and lifestyle variables with each pattern and the contributing individual metabolites. Associations statistically significant after both correction for multiple testing (False Discovery Rate = 0.05) in the discovery set and at p < 0.05 in the validation set were considered robust. Intakes of alcohol, total fish products, and its subsets total fish and lean fish were positively associated with Pattern 1. Body mass index (BMI) was positively associated with Pattern 2, which appeared to be driven by a strong positive BMI-glutamate association. Finally, both BMI and fatty fish were inversely associated with Pattern 3. In conclusion, these results indicate associations of fish and its subtypes, alcohol, and BMI with metabolite patterns that are inversely associated with risk of aggressive prostate cancer

Diet and BMI correlate with metabolite patterns associated with aggressive prostate cancer

Three metabolite patterns have previously shown prospective inverse associations with the risk of aggressive prostate cancer within the European Prospective Investigation into Cancer and Nutrition (EPIC). Here, we investigated dietary and lifestyle correlates of these three prostate cancer-related metabolite patterns, which included: 64 phosphatidylcholines and three hydroxysphingomyelins (Pattern 1), acylcarnitines C18:1 and C18:2, glutamate, ornithine, and taurine (Pattern 2), and 8 lysophosphatidylcholines (Pattern 3). In a two-stage cross-sectional discovery (n = 2524) and validation (n = 518) design containing 3042 men free of cancer in EPIC, we estimated the associations of 24 dietary and lifestyle variables with each pattern and the contributing individual metabolites. Associations statistically significant after both correction for multiple testing (False Discovery Rate = 0.05) in the discovery set and at p < 0.05 in the validation set were considered robust. Intakes of alcohol, total fish products, and its subsets total fish and lean fish were positively associated with Pattern 1. Body mass index (BMI) was positively associated with Pattern 2, which appeared to be driven by a strong positive BMI-glutamate association. Finally, both BMI and fatty fish were inversely associated with Pattern 3. In conclusion, these results indicate associations of fish and its subtypes, alcohol, and BMI with metabolite patterns that are inversely associated with risk of aggressive prostate cancer

Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

Long noncoding RNAs (lncRNAs) are commonly dys-regulated in tumors, but only a handful are known toplay pathophysiological roles in cancer. We inferredlncRNAs that dysregulate cancer pathways, onco-genes, and tumor suppressors (cancer genes) bymodeling their effects on the activity of transcriptionfactors, RNA-binding proteins, and microRNAs in5,185 TCGA tumors and 1,019 ENCODE assays.Our predictions included hundreds of candidateonco- and tumor-suppressor lncRNAs (cancerlncRNAs) whose somatic alterations account for thedysregulation of dozens of cancer genes and path-ways in each of 14 tumor contexts. To demonstrateproof of concept, we showed that perturbations tar-geting OIP5-AS1 (an inferred tumor suppressor) andTUG1 and WT1-AS (inferred onco-lncRNAs) dysre-gulated cancer genes and altered proliferation ofbreast and gynecologic cancer cells. Our analysis in-dicates that, although most lncRNAs are dysregu-lated in a tumor-specific manner, some, includingOIP5-AS1, TUG1, NEAT1, MEG3, and TSIX, synergis-tically dysregulate cancer pathways in multiple tumorcontexts